Amendment 1: Changes Table

Change History Table: Original – Amendments (1)

Amendment 1(Nov 9, 2023): BARDA BAA-23-100-SOL-00004 List of Changes:

Amendment 1 (Nov 9, 2023)

1. Updates to Overview Information –

• Updated Research and Development Opportunity Description • Updated General Market Research (TechWatch Program),
• Updated Application Process,
• Updated Contract and Submission Information,
• Updated Electronic Portal Submission Instructions

2. Updates to Background

3. Updates to Part I: Development and Technical Objectives 4. Updates to Part IV: Pre-Submission Call and Quad Chart/Market Research Abstract Instructions (Stages 1 & 2) • Updated Figure 1. BARDA BAA Process Flow Chart
• Updated Stage 1: Pre-submission Call with Technical POC 5. Updates to Part VI: Proposal Instructions (Stage 3)
• Updates to Stage 3: Proposal Precreation
o Section M. Past Performance Information &
o Vol. II, Attachment 10: Past Performance
o Vol. II, Attachment 11: Reason for the Proposed Award Type 6. Updates to Part VII: Proposal Evaluation
7. Updates to Area of Interest #6: Burn and Blast Medical Countermeasures • Updated TRL Requirement
8. Updates to Area of Interest #7: Diagnostics
• Updated AOI 7.1.3 Biothreat Agent Diagnostics: Filovirus Point-of-Care and Remote Settings • Updated AOI 7.3.1 Influenza Home-Use Testing (for OTC or Prescription At-home) • Updated AOI 7.3.3 Point-of-Care Multiplex Assay for Detection of Influenza Virus 9. Updates to Area of Interest #9: IEID Therapeutics
• Added new Area of Interest 9.4 COVID-19 Monoclonal Antibody Therapeutics for Treatment • Updated Additional Assessment Factors for the Specific Topic AOIs 10. Suspend AOI #11: COVID-19 Immune Assay(s) Development and Implementation